Organometal trihalide perovskite solar cells arguably represent the most auspicious new photovoltaic technology so far, as they possess an astonishing combination of properties. The impressive and brisk advances achieved so far bring forth highly efficient and solution processable solar cells, holding great promise to grow into a mature technology that is ready to be embedded on a large scale. However, the vast majority of state-of-the-art perovskite solar cells contains a dense TiO2 electron collection layer that requires a high temperature treatment (>450 °C), which obstructs the road towards roll-to-roll processing on flexible foils that can withstand no more than ∼150 °C. Furthermore, this high temperature treatment leads to an overall increased energy payback time and cumulative energy demand for this emerging photovoltaic technology. Here we present the implementation of an alternative TiO2 layer formed from an easily prepared nanoparticle dispersion, with annealing needs well within reach of roll-to-roll processing, making this technology also appealing from the energy payback aspect. Chemical and morphological analysis allows to understand and optimize the processing conditions of the TiO2 layer, finally resulting in a maximum obtained efficiency of 13.6% for a planar heterojunction solar cell within an ITO/TiO2/CH3NH3PbI3-xClxpoly(3-hexylthiophene)/Ag architecture.

Given the major structural role phosphodiesters play in the organism it is surprising they have not been more widely adopted as a building block in sophisticated biomimetic hydrogels and other biomaterials. The potential benefits are substantial: phosphoester‐based materials show excellent compatibility with blood, cells, and a remarkable resistance to protein adsorption that may trigger a foreign‐body response. In this work, a novel class of phosphodiester‐based ionic hydrogels is presented which are crosslinked via a phosphodiester moiety. The material shows good compatibility with blood, supports the growth and proliferation of tissue and presents opportunities for use as a drug release matrix as shown with fluorescent model compounds. The final gel is produced via base‐induced elimination from a phosphotriester precursor, which is made by the free‐radical polymerization of a phosphotriester crosslinker. This crosslinker is easily synthesized via multigram one‐pot procedures out of common laboratory chemicals. Via the addition of various comonomers the properties of the final gel may be tuned leading to a wide range of novel applications for this exciting class of materials.

A hydroxypyrone-based matrix metalloproteinase (MMP) inhibitor was synthesized and assayed for its inhibitory capacity towards a panel of ten different MMPs. The compound exhibited selective inhibition towards MMP-12. The effects of inhibition of MMP-12 on endotoxemia and inflammation-induced blood-cerebrospinal fluid barrier (BCSFB) disruption were assessed both in vitro and in vivo. Similar to MMP-12 deficient mice, inhibitor-treated mice displayed significantly lower lipopolysaccharide- (LPS-) induced lethality compared to vehicle treated controls. Following LPS injection Mmp-12 mRNA expression was massively upregulated in choroid plexus tissue and a concomitant increase in BCSFB permeability was observed, which was restricted in inhibitor-treated mice. Moreover, an LPS-induced decrease in tight junction permeability of primary choroid plexus epithelial cells was attenuated by inhibitor application in vitro. Taken together, this hydroxypyrone-based inhibitor is selective towards MMP-12 and displays anti-inflammatory activity in vitro and in vivo.

Phosphodiester hydrogels offer a wide range of fascinating properties. Not only do they exhibit excellent hemocompatibility and cellular compatibility, they also show a remarkable resistance to protein adsorption, thereby limiting the foreign body response. In this work, phosphodiester‐crosslinked hydrogels are produced by a simple free‐radical polymerization of a phosphotriester crosslinker. In a second step, this material is transformed to the phosphodiester, by heating it up to 60 °C in phosphate‐buffered saline. Compared to earlier methods, there is no need for acids, bases, or oxidizing agents to achieve this final conversion to the phosphodiester. This method thus reduces the risk to damage or degrade any sensitive biomolecules that might be of interest to tissue engineers, such as various growth factors or other proteins. The phosphotriester crosslinker is readily synthesized out of common laboratory chemicals in multigram quantities with good yield and easy workup and purification.